RxDoctor Payments Data

John Cox, MD

Ophthalmology · Huntsville, ALNPI 1477572063

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Stryker accounts for 63.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $226 and has fallen 58.7% since, to $93 in 2025. That places this record below the midpoint for ophthalmology clinicians in AL, where the typical reported total is $1,678.

$702in general payments, 2019–2025

Across 12 payments — averaging $58.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$444
  • Telix Pharmaceuticals$93
  • AbbVie$57
  • Abbott$34
  • Tersera Therapeutics LLC$20
  • AstraZeneca$20
  • plus $34 from 2 others
$117,148in ownership & investment interests, 2019–2025

Across 4 payments — averaging $29,287 each. An ownership or investment interest held by the physician or an immediate family member.

  • Vesalio, Inc.$117K
  • Stability Biologics, LLC$0

What the payments were for

  • Food & beverage$66294%
  • Education$406%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 25th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$40,455
Medicare patients
277
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Timolol Maleate108$11,373
CombiganBrimonidine Tartrate/Timolol13$3,308
Travoprost12$1,697
Brimonidine Tartrate13$1,466
Latanoprost99$1,113
Fluorometholone13$924
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$880
Prednisolone Acetate14$609
Ciprofloxacin Hcl23$348
Acyclovir13$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$57$3,30813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →